EC tells Valneva it's terminating APA deal on COVID-19 vaccine

17 May 2022

French specialty vaccine company Valneva (Euronext: VLA) yesterday announced that it has received a notice from the European Commission (EC) of intent to terminate the advance purchase agreement (APA) for Valneva’s inactivated whole-virus COVID-19 vaccine candidate VLA2001.

Valneva’s shares fell on the news, but recovered to some extent today, with the stock up 5.7% at 10.20 euros mid-afternoon.

The APA provides the EC with a right to terminate the APA if VLA2001 had not received a marketing authorization from the European Medicines Agency (EMA) by April 30, 2022. Based on the terms of the APA, Valneva has 30 days from May 13, 2022, to obtain a marketing authorization or propose an acceptable remediation plan.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK